TransMedics Group, Inc. (NASDAQ:TMDX - Get Free Report) Director Edward M. Basile sold 5,000 shares of TransMedics Group stock in a transaction on Tuesday, May 27th. The shares were sold at an average price of $126.45, for a total value of $632,250.00. Following the transaction, the director now owns 2,866 shares in the company, valued at approximately $362,405.70. This trade represents a 63.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
TransMedics Group Price Performance
Shares of NASDAQ:TMDX traded up $4.80 during midday trading on Tuesday, reaching $128.74. 893,951 shares of the company's stock were exchanged, compared to its average volume of 1,357,796. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. The firm has a market capitalization of $4.35 billion, a PE ratio of 136.96 and a beta of 1.91. TransMedics Group, Inc. has a 12 month low of $55.00 and a 12 month high of $177.37. The company's 50 day simple moving average is $96.37 and its two-hundred day simple moving average is $78.80.
TransMedics Group (NASDAQ:TMDX - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.29 by $0.41. TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The firm had revenue of $143.54 million during the quarter, compared to the consensus estimate of $123.39 million. During the same quarter in the previous year, the company posted $0.35 EPS. The business's revenue for the quarter was up 48.2% compared to the same quarter last year. Equities research analysts expect that TransMedics Group, Inc. will post 1 earnings per share for the current fiscal year.
Institutional Investors Weigh In On TransMedics Group
A number of institutional investors and hedge funds have recently made changes to their positions in the company. Clear Creek Financial Management LLC bought a new stake in TransMedics Group in the fourth quarter valued at about $352,000. Vaughan Nelson Investment Management L.P. increased its stake in TransMedics Group by 9.9% in the fourth quarter. Vaughan Nelson Investment Management L.P. now owns 361,615 shares of the company's stock valued at $22,547,000 after purchasing an additional 32,605 shares in the last quarter. Baillie Gifford & Co. increased its stake in TransMedics Group by 14.9% in the fourth quarter. Baillie Gifford & Co. now owns 269,836 shares of the company's stock valued at $16,824,000 after purchasing an additional 34,947 shares in the last quarter. State of Michigan Retirement System bought a new stake in TransMedics Group in the fourth quarter valued at approximately $6,734,000. Finally, Peregrine Capital Management LLC increased its stake in TransMedics Group by 64.0% in the fourth quarter. Peregrine Capital Management LLC now owns 66,140 shares of the company's stock valued at $4,124,000 after purchasing an additional 25,814 shares in the last quarter. Institutional investors own 99.67% of the company's stock.
Analyst Ratings Changes
A number of research analysts have recently weighed in on the company. Needham & Company LLC reiterated a "hold" rating on shares of TransMedics Group in a report on Tuesday. Piper Sandler restated an "overweight" rating and issued a $125.00 target price (up previously from $105.00) on shares of TransMedics Group in a research note on Friday, May 9th. Oppenheimer boosted their price target on TransMedics Group from $125.00 to $130.00 and gave the company an "outperform" rating in a research note on Friday, May 9th. Finally, Canaccord Genuity Group reissued a "buy" rating and issued a $104.00 target price on shares of TransMedics Group in a research report on Tuesday, March 11th. Three equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, TransMedics Group has a consensus rating of "Moderate Buy" and an average target price of $126.70.
Check Out Our Latest Research Report on TMDX
TransMedics Group Company Profile
(
Get Free Report)
TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.
Featured Stories
Before you consider TransMedics Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TransMedics Group wasn't on the list.
While TransMedics Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
